Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research.

[1]  P. Brauchli,et al.  Trastuzumab beyond progression: a cost-utility analysis. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  R. Kreienberg,et al.  First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Yan Sun,et al.  Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Bergh,et al.  8N Similar outcome in a randomized phase III trial comparing docetaxel versus vinorelbine both combined with trastuzumab as first line treatment for metastatic or locally advanced human epidermal growth factor receptor 2 (HER2) positive breast cancer , 2010 .

[5]  J. Baselga,et al.  Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Gelmon,et al.  Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Jassem,et al.  Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Baselga,et al.  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort , 2010, The Lancet.

[9]  G. Hortobagyi,et al.  Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Y. Yamashita,et al.  Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy , 2010, Cancer Chemotherapy and Pharmacology.

[11]  H. Rugo,et al.  A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody–Drug Conjugate, in HER2+ Metastatic Breast Cancer (MBC) Patients Previously Treated with Conventional Chemotherapy, Lapatinib and Trastuzumab. , 2009 .

[12]  P. Fasching,et al.  Letrozole in Combination with Trastuzumab Is Superior to Letrozole Monotherapy as First Line Treatment in Patients with Hormone-Receptor-Positive, HER2- Positive Metastatic Breast Cancer (MBC) – Results of theeLEcTRATrial. , 2009 .

[13]  D. Elashoff,et al.  Final Results of a Phase II Trial Evaluating Trastuzumab and Bevacizumab as First Line Treatment of HER2-Amplified Advanced Breast Cancer. , 2009 .

[14]  J. Mackey,et al.  Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  B. Leyland-Jones.  Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Baselga,et al.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 , 2009, Nature Reviews Cancer.

[17]  S. Loibl,et al.  Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Tolaney,et al.  Mechanisms of trastuzumab resistance in breast cancer. , 2009, Anti-Cancer Agents in Medicinal Chemistry.

[19]  R. Greil,et al.  Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer , 2009, Clinical Cancer Research.

[20]  M. Birkner,et al.  Survival of patients with HER2+ metastatic breast cancer and use of trastuzumab following progression: analysis of RegistHER. , 2009 .

[21]  H. Gómez,et al.  Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial. , 2009 .

[22]  D. Larsimont,et al.  Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors. , 2009 .

[23]  E. Mallon,et al.  Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours , 2008, British Journal of Cancer.

[24]  B. Nam,et al.  Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  M. Dimopoulos,et al.  A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer , 2009, Breast Cancer Research and Treatment.

[26]  A. Gown,et al.  Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  K. Pritchard,et al.  Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. , 2008, Cancer treatment reviews.

[28]  G. Botti,et al.  Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era. , 2008, Clinical breast cancer.

[29]  M. Mottolese,et al.  Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. , 2008, Breast.

[30]  D. Richel,et al.  Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  J. Hainsworth,et al.  Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC) , 2008 .

[32]  J. Baselga,et al.  A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy , 2008 .

[33]  J. Klijn,et al.  Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first-line chemotherapy in HER2-neu positive, metastatic breast cancer (MBC) (HERTAX study) , 2008 .

[34]  T. Cosgriff,et al.  Single-agent nab-paclitaxel given weekly (3/4) as first-line therapy for metastatic breast cancer (an International Oncology Network study, #I-04-012) , 2008 .

[35]  S. Ménard.  Observational Demetra study: Survival of metastatic breast carcinoma patients after treatment with trastuzumab , 2008 .

[36]  D. Lake,et al.  Phase II study of weekly nanoparticle albumin bound (nab)paclitaxel with carboplatin and trastuzumab as 1st-line therapy for HER2-positive metastatic breast cancer (MBC) , 2008 .

[37]  A. D. Van den Abbeele,et al.  Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  N. Pavlidis,et al.  Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety. , 2008, Critical reviews in oncology/hematology.

[39]  M. Gnant,et al.  Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer , 2008, Cancer Chemotherapy and Pharmacology.

[40]  M. Milella,et al.  Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer. , 2007, The oncologist.

[41]  Michael Gnant,et al.  Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  R. Ward,et al.  Trastuzumab and metastatic breast cancer: trastuzumab use in Australia--monitoring the effect of an expensive medicine access program. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  A. Hinke,et al.  Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  C. Vogel,et al.  Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer. , 2007, Clinical breast cancer.

[45]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[46]  A. Chan,et al.  A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  J. Forbes,et al.  BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC) , 2007 .

[48]  E. Villar-Chamorro,et al.  Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study , 2007, Breast Cancer Research.

[49]  G. Steger,et al.  Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer , 2007, Journal of Neuro-Oncology.

[50]  E. Winer,et al.  Brain Metastases: The HER2 Paradigm , 2007, Clinical Cancer Research.

[51]  D. Amadori,et al.  Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer , 2007, Breast Cancer Research and Treatment.

[52]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[53]  G. Pond,et al.  Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  N. Robert,et al.  Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  L. Chen,et al.  A phase II trial of trastuzumab (H) + capecitabine (X) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer (MBC). , 2006, Journal of Clinical Oncology.

[56]  J. Abraham,et al.  Phase II study of gemcitabine (Gem) and trastuzumab (T) combination therapy in first line metastatic breast cancer (MBC) patients (pts) with HER2 overexpression. , 2006, Journal of Clinical Oncology.

[57]  L. Bosserman,et al.  A phase II study of neoadjuvant docetaxel/carboplatin with or without trastuzumab in locally advanced breast cancer: Response and cardiotoxicity. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  J. Forbes,et al.  BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  M. Martín,et al.  Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  G. Steger,et al.  Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study , 2006, BMC Cancer.

[61]  V. Heinemann,et al.  Prolonged Survival of Patients Receiving Trastuzumab beyond Disease Progression for HER2 Overexpressing Metastatic Breast Cancer (MBC) , 2005, Oncology Research and Treatment.

[62]  David Grimes,et al.  Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  Terry L. Smith,et al.  Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  J. Baselga,et al.  Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  B. Leyland-Jones,et al.  Clinical benefit of trastuzumab (H) among patients with HER2-positive metastatic breast cancer (MBC) not achieving objective responses when treated with H plus chemotherapy (CT) , 2004 .

[66]  J. O’Shaughnessy,et al.  Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. , 2004, Clinical breast cancer.

[67]  W. Eiermann,et al.  Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. , 2004, Journal of the National Cancer Institute.

[68]  D. Slamon,et al.  Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. , 2004, Journal of the National Cancer Institute.

[69]  Suzanne F. Jones,et al.  Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  A. Schneeweiss,et al.  Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. , 2004, Clinical breast cancer.

[71]  M. Cobleigh,et al.  Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  H. Gogas,et al.  Paclitaxel and Gemcitabine, As First-Line Chemotherapy, Combined with Trastuzumab in Patients with Advanced Breast Cancer: A Phase II Study Conducted by the Hellenic Cooperative Oncology Group (HeCOG) , 2004, Cancer investigation.

[73]  H. Gogas,et al.  Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. , 2003, Clinical breast cancer.

[74]  K. Fujimoto-Ouchi,et al.  Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast cancer models , 2002, Cancer Chemotherapy and Pharmacology.

[75]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[76]  M. Sliwkowski,et al.  Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers , 1999, Oncogene.

[77]  R. Finn,et al.  Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs , 1998, Oncogene.

[78]  D Tripathy,et al.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  D. Taverna,et al.  Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. , 1990, Oncogene.

[80]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.